XLO - Xilio Development Inc

Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune systems of cancer patients. The company is headquartered in Waltham, Massachusetts.

52W High

$1.70

52W Low

$0.62

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.11

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.11

EV/Revenue (<3 favorable)

1.95

P/S (TTM) (<3 favorable)

2.42

P/B (<3 favorable)

5.13

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

45.72%

Institutions (25–75% balanced)

25.42%

Shares Outstanding

51,828,000

Float

23,434,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

15,001,000

Gross Profit (TTM)

13,021,000

EPS (TTM)

-0.70

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-1.78%

ROE (TTM) (>15% strong)

-2.78%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

2.43

Momentum

Bearish momentum

Value

0.0138

0.0128

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025